Oct 30 2009
Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") announced that a poster presentation covering updated results of a Phase II study of REOLYSIN(R) administered intravenously to patients with sarcomas metastatic to the lung will be presented at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting being held in Miami Beach, Florida on November 6th, 2009.
The poster presentation, entitled "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) in the Treatment of Patients with Bone and Soft Tissue Sarcomas Metastatic to the Lung" will be delivered by Dr. Kamalesh Sankhala, part of principal investigator Dr. Monica Mita's team at the Institute of Drug Development (IDD), the Cancer Therapy and Research Center at the University of Texas Health Science Center, (UTHSC), San Antonio, Texas.
SOURCE Oncolytics Biotech Inc.